Psilocybin is under clinical development by Filament Health and currently in Phase I for Major Depressive Disorder.

ABX-002 is under clinical development by Autobahn Therapeutics and currently in Phase II for Major Depressive Disorder.

Neumora Therapeutics Inc.’s stock tumbled 80% Thursday, after the clinical-stage biotech said a late-stage trial of a ...

The National Institute of Mental Health defines depression, which is also known as clinical depression or major depressive ...

Medically reviewed by Dakari Quimby, PhD Male postpartum depression describes when a new father experiences postpartum ...

In this longitudinal cohort study of older drivers, adults with major depressive disorder demonstrated distinct and riskier driving behaviors than those in the control group without depression, with ...

People explore different treatments and therapies to help with depression, and recently, researchers wanted to understand if ...

DEPRESSIVE disorder (also known as depression) is a mental health condition that causes a chronic feeling of emptiness, sadness, or inability to feel ...

Navacaprant is an highly selective kappa opioid receptor antagonist expected to modulate reward processing pathways and mediate depressive states.

Neumora Therapeutics Inc.’s shares plummeted after the company’s experimental drug failed to show a benefit in a final-stage ...

Neumora Therapeutics (NMRA) crashed after its Phase 3 study for its lead asset navacaprant in major depressive disorder ...

Neumora Therapeutics Inc. (NASDAQ: NMRA) nosedived by more than 80 percent during pre-market trading following disappointing ...